Ziihera (zanidatamab-hrii), a therapeutic antibody developed using ProBioGen’s proprietary GlymaxX technology, has become commercially available. Following FDA approval late last year for the treatment of HER2-positive biliary tract cancer (BTC), this milestone represents a step forward in targeted cancer therapy.

“The market availability of a bispecific therapeutic antibody developed with the GlymaxX technology represents an important milestone,” said Dr. Gabriele Schneider, Chief Business Officer at ProBioGen. “It is rewarding to see our technology play a role in therapies that can make a real difference for patients. We are proud to have contributed to Ziihera’s journey by providing our cell line, media, and our proprietary technology to help bring this innovative treatment to market. We look forward to continuing to support groundbreaking advancements in biopharmaceuticals.”

The company expects further GlymaxX-enabled achievements in the near future.